GuangZhou Cellgenes Biotechnology

CompanyChina

GuangZhou Cellgenes Biotechnology develops one asset, in phase 1 (CG-BM1 in sarcopenia). Mostly cell therapy; based in China.

1
Asset
Furthest stage
Phase 1
1
Trial
1
Signal

Pipeline

1
  • CG-BM1

    Allogeneic human bone marrow mesenchymal stem cell therapy intended to treat sarcopenia.

    Phase 1, Cell therapy, sarcopenia

Full company profiles: pipeline, trials, funding and people.

See Pro

In the full profile

  • Trials1
  • Signals1
  • Similar companies6

Intelligence